title: [Pharmacokinetics of cis-platinum diammine dichloride].
abstract: Levels of cis-platinum diammine dichloride (CPDD) were determined in the serum, urine and ascites by the flameless atomic absorption spectrophotometry. Samples were obtained from the patients with ovarian cancer (5 cases) and cervical cancer (1 case). The patients were given CPDD by infusion every three weeks. The treatment schedules were as follows: A, 14-16 mg/body/day X 5 days; B, 20 mg/body/day X 5 days; C, 50 mg/body X 1 day. The levels of CPDD in the serum of the patients treated under schedules A and B became higher after the repeated administration from day 1 through 5. In the patients treated under schedules A and B, a more complex serum elimination curve was seen, while a simple biphasic clearance pattern was observed in the patient treated under schedule C. The concentration of CPDD in the serum arose with the increase of doses. A measurable concentration of CPDD was still detected 14 days after the end of administration. The urinary recovery at 24 hours after administration of CPDD ranged from 17.0 to 21.0% under schedules A and B. On the other hand, it was 54.2% under schedule C. The overall urinary recovery of CPDD ranged from 25.3 to 35.3% which suggested the retention of CPDD. The urinary excretion of CPDD and the concentration of CPDD in urine showed close relation with a urine volume per hour. The levels of CPDD remained lower in the ascites compared to those of the serum. No significant elevation in the serum creatinine or BUN were recognized in all patients.
mesh_terms: D001201:Ascites / Q000378:metabolism; D002945:Cisplatin / Q000008:administration & dosage / Q000378:metabolism* / Q000633:toxicity; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects; D007700:Kinetics; D010051:Ovarian Neoplasms / Q000188:drug therapy; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy
chemical_list: D002945:Cisplatin